$BODFS 1SPHSBN "OOVBM 3FQPSU
!PPROVED #ANCER 0ROGRAMS
.BSZ #JSE 1FSLJOT $BODFS $FOUFS
4U 5BNNBOZ 1BSJTI )PTQJUBM
( , )''#.. *ACK 3AUX -$ (EMATOLOGY /NCOLOGY #ANCER #OMMITTEE #HAIRMAN 'REG (ENKELMANN -$ 2ADIATION /NCOLOGY #ANCER ,IAISON 0HYSICIAN $EBBIE "RUNO !24 2 - !SSISTANT $EPARTMENT (EAD )MAGING 3ERVICES 340(
)/, '#--#)( 4O PROVIDE THE HIGHEST QUALITY CANCER CARE AND TO MEET THE NEEDS OF THE COMMUNITY WITH EDUCATIONAL SEMINARS SUPPORT GROUPS AND HEALTH SCREENINGS
#HRYL #ORIZZO 2. "3. /#. #ANCER 0ROGRAM $IRECTOR 340( .ICOLE -AGEE #42 4UMOR 2EGISTRY $IRECTOR -"0## 6ICKIE (ALL ,0. 24 4 $IRECTOR -"0## #OVINGTON #HERYL 'ILES 2. #(0. $IRECTOR (OSPICE 340( *AMES ,ACOUR -$ 2ADIOLOGY *UDY ,IMBAUGH -$ 0ATHOLOGY 0ATRICIA -ALTESE 24 -(! $EPARTMENT (EAD )MAGING 3ERVICES 340( +ATHY -C7HORTER 2. -3. $IRECTOR OF .URSING 340( ,ORI -C#ALLUM -%D #42 %XECUTIVE $IRECTOR # ! 2 % .ETWORK $AVID /UBRE -$ (EMATOLOGY /NCOLOGY 4ERESA 0ALOMBO 2. "3. %4 $EPARTMENT (EAD -EDICAL /NCOLOGY 5NIT 340( 4ONYA *ACKSON 2AMSEY (EALTH )NITIATIVES 2EPRESENTATIVE !#3 *UANITA 3CHENCK ,#37 #ASE -ANAGEMENT 340( 3USAN 3TAHL 2EGISTRY &OLLOW UP #LERK 340( "RENDA 4RUXILLO 2. 6ICE 0RESIDENT 2ADIATION /NCOLOGY 3ERVICES -"0## *OHN 6ERHULST -$ 'ENERAL 3URGERY "EVERLY 6ILLEMUER #42 2EGISTRAR 340( *O 7ATKINS 20H #LINICAL 0HARMACY #OORDINATOR 340(
" #,' ( - , *),. !S #HAIRMAN OF THE -ARY "IRD 0ERKINS #ANCER #ENTER -"0## AND 3T 4AMMANY 0ARISH (OSPITAL 340( #ANCER #OMMITTEE ) AM PLEASED TO PRESENT THE #ANCER 0ROGRAM !NNUAL 2EPORT "ECAUSE OF THE IMPACT OF (URRICANE +ATRINA THIS REPORT WILL REmECT BOTH AND 2EGISTRY DATA 4HE HIGHLIGHT OF THIS REPORT IS TO ANNOUNCE THAT -"0## AND 340( WERE EACH AWARDED A THREE YEAR APPROVAL STATUS WITH COMMENDATION FROM THE #OMMISSION ON #ANCER OF THE !MERICAN #OLLEGE OF 3URGEONS !#O3 AS APPROVED #ANCER 0ROGRAMS 4HERE ARE APPROXIMATELY APPROVED CANCER PROGRAMS IN THE NATION REPRESENTING ABOUT PERCENT OF ALL ACUTE CARE FACILITIES BUT THESE APPROVED FACILITIES DIAGNOSE AND TREAT PERCENT OF ALL CANCER PATIENTS IN THE 5NITED 3TATES AND 0UERTO 2ICO )N ADDITION THE MAJORITY OF APPROVED FACILITIES ARE IN SMALL COMMUNITY SETTINGS ENSURING PATIENTS AND THEIR FAMILIES QUALITY CANCER CARE CLOSE TO HOME )N SPITE OF THE EVENTS THAT OCCURRED IN LATE MEMBERS OF THE -"0## 340( #ANCER #OMMITTEE ACCOMPLISHED SEVERAL GOALS RELATED TO MANY ASPECTS OF CANCER SERVICES PROVIDED TO PATIENTS CAREGIVERS HEALTH PROFESSIONALS AND THE COMMUNITY -"0## AND 340( PARTNERED WITH THE !MERICAN #ANCER 3OCIETY !#3 TO PROMOTE CANCER SCREENING GUIDELINES TO PRIMARY CARE PHYSICIANS AND MEMBERS OF OUR COMMUNITY 4HIS PARTNERSHIP RESULTED IN !#3 ESTABLISHING THE .ORTHSHORE 0ARTNERS OF (OPE PROGRAM TO PROVIDE ASSISTANCE DIRECTLY TO CANCER PATIENTS TREATED LOCALLY ON THE .ORTHSHORE 3INCE INCEPTION OF THIS PROGRAM APPROXIMATELY INDIVIDUALS HAVE OBTAINED TRANSPORTATION ASSISTANCE VIA GAS CARDS AND OR NUTRITIONAL SUPPLEMENTS -"0## AND 340( ALSO PARTNERED WITH THE (EMATOLOGY /NCOLOGY 3PECIALISTS &OUNDATION TO OFFER THE lRST ANNUAL #ANCER 3URVIVORS $AY EDUCATIONAL EVENT ENTITLED h,IVING 4HROUGH AND !FTER A #ANCER $IAGNOSIS #ARING FOR THE "ODY -IND AND 3PIRIT v 4HE FACT THAT THE PROGRAM FORMAT WAS REQUESTED BY SURVIVORS AND THAT CLOSE TO ATTENDEES PARTICIPATED ATTESTS TO HOW GREAT THE NEED IS FOR INFORMATION RELATED TO LIVING LIFE AFTER A CANCER DIAGNOSIS -"0## AND 340( ALSO EVALUATED THE MANAGEMENT AND OUTCOMES OF PATIENTS WITH PROSTATE CANCER DIAGNOSED AND OR TREATED JOINTLY BETWEEN THEIR INSTITUTIONS 4HE RESULTS OF THAT STUDY ARE INCLUDED IN THIS REPORT /THER 340( IMPROVEMENT INITIATIVES FOCUSED ON MEETING #OLLEGE OF !MERICAN 0ATHOLOGY REPORTING BENCHMARKS SUGGESTED BY THE !#O3 #OMMISSION ON #ANCER TO IMPROVE THE QUALITY OF PATHOLOGY SPECIMEN REPORTING ! DIGITAL CAMERA DESIGNED TO SPECIlCALLY TAKE IMAGES OF PATHOLOGY SLIDES ENABLED THE 0ATHOLOGISTS TO SIGNIlCANTLY IMPROVE THE QUALITY AND EASE OF PRESENTATIONS AT THE MONTHLY PHYSICIAN 4UMOR #ONFERENCES "ASED ON IDENTIlED NEEDS 2ADIOLOGY OBTAINED AN ADDITIONAL NUCLEAR MEDICINE CAMERA AND THE CAPABILITY TO PERFORM -AGNETIC 2ESONANCE )MAGING -2) OF THE BREAST -ARY "IRD 0ERKINS #ANCER #ENTER IS THE ONLY COMPREHENSIVE RADIATION THERAPY TREATMENT CENTER IN THE REGION OFFERING TAILORED SOLUTIONS TO COMPLEX CANCER CARE AND NON CANCEROUS CONDITIONS )TS EXPERT RADIATION TREATMENT TEAM IS THE LARGEST AND MOST EXPERIENCED IN ,OUISIANA TREATING MORE PATIENTS WITH RADIATION THERAPY THAN ANY OTHER FACILITY IN THE sTATE )N RECENT YEARS -ARY "IRD 0ERKINS HAS INVESTED OVER MILLION TO BRING SOUTHEAST ,OUISIANA RESIDENTS THE MOST ADVANCED RADIATION THERAPY AVAILABLE IN THE WORLD INCLUDING INTENSITY MODULATED RADIATION THERAPY )-24 ADVANCED IMAGE GUIDED RADIATION THERAPY )'24 THROUGH "RAIN,!" .OVALIS AND THE 4OMO4HERAPY () !24 3YSTEM STEREOTACTIC RADIOSURGERY ADAPTIVE RADIOTHERAPY AND FOUR DIMENSIONAL #4 TUMOR LOCALIZATION -ARY "IRD 0ERKINS HAS AN EXCLUSIVE RESEARCH PARTNERSHIP WITH ,OUISIANA 3TATE 5NIVERSITY TO DISCOVER NEW CANCER TREATMENTS ENABLING THE #ENTER TO ATTRACT THE BRIGHTEST MINDS IN CANCER TREATMENT TO OUR REGION /N BEHALF OF MYSELF AND THE MEMBERS OF THE -"0## 340( #ANCER #OMMITTEE WE HOPE YOU WILL ENJOY THE #ANCER 0ROGRAM !NNUAL 2EPORT *ACK % 3AUX ))) -$ #ANCER #OMMITTEE #HAIR
-"0## 340( #!.#%2 02/'2!- !..5!, 2%0/24
(),."-"), ( , & ,- ,( ( .#)( & , )!(#.#)( 340( AND -"0## %ARN !PPROVAL WITH #OMMENDATION BY #OMMISSION ON #ANCER OF !MERICAN #OLLEGE OF 3URGEONS 4HE #OMMISSION ON #ANCER OF THE !MERICAN #OLLEGE OF 3URGEONS HAS GRANTED A THREE YEAR APPROVAL STATUS WITH COMMENDATION TO THE #ANCER 0ROGRAMS OF -ARY "IRD 0ERKINS #ANCER #ENTER AND 3T 4AMMANY 0ARISH (OSPITAL IN #OVINGTON 2ECEIVING CARE AT A #OMMISSION ON #ANCER #O# APPROVED CANCER PROGRAM ENSURES THAT A PATIENT WILL HAVE ACCESS TO QUALITY CARE CLOSE TO HOME COMPREHENSIVE CARE INCLUDING A RANGE OF STATE OF THE ART SERVICES AND EQUIPMENT A MULTI SPECIALTY TEAM APPROACH TO COORDINATE THE BEST TREATMENT OPTIONS INFORMATION ABOUT ONGOING CLINICAL TRIALS NEW TREATMENT OPTIONS EDUCATION AND SUPPORT LIFELONG PATIENT FOLLOW UP THROUGH A CANCER REGISTRY THAT COLLECTS DATA ON TYPE AND STAGE OF CANCERS AND TREATMENT RESULTS AND ONGOING MONITORING AND IMPROVEMENT OF CARE
!PPROVAL BY THE #O# IS GIVEN ONLY TO THOSE FACILITIES THAT HAVE VOLUNTARILY COMMITTED TO PROVIDE THE BEST IN CANCER DIAGNOSIS TREATMENT AND SUPPORTIVE SERVICES AND TO UNDERGO A RIGOROUS EVALUATION PROCESS AND PERFORMANCE REVIEW )N ORDER TO MAINTAIN APPROVAL FACILITIES WITH APPROVED CANCER PROGRAMS ARE SUBJECT TO AN ON SITE REVIEW EVERY THREE YEARS #OMPONENTS ESSENTIAL TO THE SUCCESS OF THE CANCER PROGRAM ARE A MULTIDISCIPLINARY CANCER COMMITTEE CANCER CONFERENCES QUALITY MANAGEMENT PROGRAM CANCER DATA MANAGEMENT SYSTEM CANCER REGISTRY AND PROFESSIONAL AND PUBLIC EDUCATION 4HE #ANCER 0ROGRAM AT 3T 4AMMANY 0ARISH (OSPITAL AND -ARY "IRD 0ERKINS #ANCER #ENTER IS ONE OF FEWER THAN SUCH PROGRAMS IN THE NATION ACCREDITED BY THE !MERICAN #OLLEGE OF 3URGEONS #OMMISSION ON #ANCER AND THE ONLY APPROVED CANCER PROGRAM IN 7EST 3T 4AMMANY 0ARISH 4HIS STATUS EQUATES TO QUALITY CANCER CARE n ONLY OF THE HOSPITALS IN THE COUNTRY ARE APPROVED CANCER PROGRAMS BUT THEY DIAGNOSE AND TREAT OF CANCER PATIENTS
-"0## 340( #!.#%2 02/'2!- !..5!, 2%0/24
4OGETHER -ARY "IRD 0ERKINS #ANCER #ENTER -"0## AND 3T 4AMMANY 0ARISH (OSPITAL 340( COORDINATE THE ENTIRE CONTINUUM OF CANCER CARE 2ADIATION ONCOLOGY IS AVAILABLE AT -"0## AND DIAGNOSTIC AND REHABILITATIVE MODALITIES SURGERY AND MEDICAL ONCOLOGY ARE AVAILABLE AT 340( !LTHOUGH ORGANIZATIONALLY INDEPENDENT -"0## AND 340( COLLABORATE CLOSELY WITH ONE ANOTHER TO PROMOTE A SEAMLESS MULTIDISCIPLINARY CANCER TREATMENT DELIVERY SYSTEM FOR PATIENTS AND THEIR FAMILIES 3ERVING A PARISH AREA -"0## TREATS MORE PATIENTS WITH RADIATION THERAPY THAN ANY OTHER FACILITY IN THE STATE 4HE COMBINED SIZE AND EXPERTISE OF THE #ENTER S TEAM OF TEN MEDICAL PHYSICISTS SIX MEDICAL DOSIMETRISTS AND SIX RADIATION ONCOLOGISTS CANNOT BE FOUND ELSEWHERE IN ,OUISIANA 4HROUGH ITS JOINT RESEARCH AND ACADEMIC PARTNERSHIP WITH ,OUISIANA 3TATE 5NIVERSITY S $EPARTMENT OF 0HYSICS AND !STRONOMY ADVANCES ARE BEING MADE IN RADIATION THERAPY AND MEDICAL IMAGING RESEARCH -"0## CREATED THE # ! 2 % .ETWORK IN TO ADDRESS ,OUISIANA S INORDINATELY HIGH CANCER MORTALITY RATES )NTENT UPON PROVIDING INCREASED SCREENING SERVICES TO THE MEDICALLY UNDERSERVED AND ULTIMATELY LOWERING CANCER MORTALITY RATES IN ITS SERVICE AREA AND BEYOND IT NOW HAS THE ONLY MOBILE MEDICAL CLINIC THE %ARLY "IRD IN THE AREA DEDICATED TO COMPREHENSIVE COMMUNITY CANCER SCREENINGS 4HE %ARLY "IRD IS EXPANDING FREE SCREENINGS DIRECTLY INTO RURAL REMOTE COMMUNITIES 4HE # ! 2 % .ETWORK HELD NEARLY SCREENINGS IN )T HAS ALSO PROVIDED BREAST CANCER SCREENINGS IN .EW /RLEANS WHERE THERE ARE CURRENTLY NO SCREENING MAMMOGRAPHY SERVICES AVAILABLE TO UNINSURED WOMEN AND TO &%-! TRAILER VILLAGES
2ESIDENTS CHOOSE 340( THE LEADING PROVIDER OF COMPREHENSIVE MEDICAL CARE ON THE .ORTHSHORE MORE THAN ANY OTHER HEALTH CARE RESOURCE !S THE ONLY APPROVED COMMUNITY HOSPITAL CANCER PROGRAM IN 7EST 3T 4AMMANY 0ARISH ACCREDITED BY THE !MERICAN #OLLEGE OF 3URGEONS PATIENTS ON THE .ORTHSHORE ARE ABLE TO RECEIVE THE HIGHEST QUALITY CARE THEY COULD EXPECT ANYWHERE RIGHT HERE AT HOME &ROM WELLNESS AND PREVENTION TO DIAGNOSIS TREATMENT REHABILITATION AND RECOVERY THE 3T 4AMMANY 0ARISH (OSPITAL SYSTEM DELIVERS THE VERY LATEST TECHNOLOGY THE MOST ACCOMPLISHED SPECIALISTS AND HIGHLY PERSONALIZED CARING STAFF TO ENSURE PATIENTS AND THEIR FAMILIES RECEIVE WORLD CLASS HEALTH CARE CLOSE TO HOME )N ADDITION TO ITS CANCER PROGRAM APPROVAL STATUS THROUGH THE !#O3 AS A #OMMUNITY (OSPITAL #ANCER 0ROGRAM 340( EARNED THE *OINT #OMMISSION ON !CCREDITATION OF (EALTHCARE /RGANIZATIONS 'OLD 3EAL OF !PPROVAL 3OLUCIENT )NSIGHT !WARDS FOR #LINICAL AND /VERALL %XCELLENCE 6(! ,EADERSHIP !WARDS FOR #LINICAL %XCELLENCE AND RECOGNITION FOR EXCELLENCE AS AN EMPLOYER INCLUDING #ITY"USINESS "EST 0LACES TO 7ORK AND THE NATIONAL %MPLOYER OF #HOICE DISTINCTION WHICH PLACES 3T 4AMMANY AMONG THE TOP OF EMPLOYERS IN THE NATION 4HE 340( #ANCER 2ESOURCE #ENTER SERVES TO ASSIST THOSE DIAGNOSED WITH CANCER AND THEIR CAREGIVERS THROUGHOUT THEIR CANCER EXPERIENCE )NFORMATION IS AVAILABLE ON CANCER PREVENTION EARLY DETECTION CANCER TREATMENT SURVIVORSHIP AND COPING RESOURCES ! 7IG 2ESOURCE #ENTER IS AVAILABLE AS WELL AS A PATIENT LIBRARY WITH INTERNET ACCESS
-"0## 340( #!.#%2 02/'2!- !..5!, 2%0/24
( , *,)!, ' -/**),.#0
( )(.#(/#(! , - ,0# -
-"0##
340(
$)!'./34)# 3%26)#%3
"REAST #ENTER
-AMMOGRAPHY "ONE $ENSITY 3TEREOTACTIC .EEDLE "IOPSY
5LTRASOUND $EDICATED 2ADIOLOGISTS WITH 3PECIALTY IN "REAST $ISEASE
0ATHOLOGY ,ABORATORY
2ADIOLOGY
#4 3CANNER 5LTRASOUND .UCLEAR -EDICINE -2)
42%!4-%.4 3%26)#%3
)NPATIENT -EDICAL /NCOLOGY 5NIT
/UTPATIENT )NFUSION 5NIT 0ATIENT 3CHEDULING
2ADIATION 4HERAPY
%XTERNAL "EAM 2ADIOTHERAPY
)NTENSITY -ODULATED 2ADIATION 4HERAPY )-24
0ROSTATE 3EED )MPLANTATION
2ADIATION 4REATMENT 0LANNING
)MAGE &USION
-EDICAL 0HYSICS $OSIMETRY
6IRTUAL 3IMULATION
3URGERY
3500/24)6% 2%(!"),)4!4)6% 3%26)#%3
#ARDIAC 2EHABILITATION
#ANCER #OMMITTEE
%NTEROSTOMAL 7OUND 4HERAPY
%THICS #OMMITTEE
(OME (EALTH
(OSPICE
.UTRITIONAL 3ERVICES
0ASTORAL #ARE #LERGY #OMMUNITY 3UPPORT
0ATIENT &INANCIAL #OUNSELOR
0HARMACY
0HYSICAL /CCUPATIONAL 3PEECH 4HERAPY
0ULMONARY 2EHABILITATION
3OCIAL 3ERVICES #ASE -ANAGEMENT
-"0## 340( #!.#%2 02/'2!- !..5!, 2%0/24
( , *,)!, ' -/**),.#0
( )(.#(/#(! , - ,0# -
-"0##
340(
#/--5.)49 /542%!#( !.$ %$5#!4)/.
#ANCER 2ISK !SSESSMENTS
#ANCER 3CREENINGS
#ANCER 2ESOURCE #ENTER
#AMP #OURAGE "EREAVEMENT #AMP FOR #HILDREN
#ANCER #ONNECTION .EWSLETTER
#ANCER -EMORIAL 0LAQUE 0ROGRAM
%DUCATION FOR (EALTH 0ROFESSIONALS
#ONTINUING -EDICAL %DUCATION
#ONTINUING .URSING %DUCATION
-ULTIDISCIPLINARY 4UMOR #ONFERENCES
%LDER 3ERVICES
'ENETIC #ANCER 2ISK !SSESSMENT #OUNSELING 0ROGRAM
(OSPICE -EMORIAL 3ERVICES AND #OMMUNITY .EWSLETTER
,OOK 'OOD &EEL "ETTER
,YMPHEDEMA 0REVENTION #LINICS
0ATIENT ,IBRARY
0AIN -ANAGEMENT
0ATIENT 4RANSPORTATION
2EACH TO 2ECOVERY 6OLUNTEER 6ISITATION
3PEAKERS "UREAU
4OBACCO #ESSATION #LASSES )NFORMATION
7EIGHT AND 3TRESS #ONTROL 0ROGRAMS
7IG 2ESOURCE #ENTER
"EREAVEMENT 3UPPORT 'ROUP ADULTS CHILDREN
"ETTER "REATHERS 3UPPORT 'ROUP
"REAST #ANCER 3UPPORT 'ROUP
#ANCER #ONNECTION 3UPPORT 'ROUP
#AREGIVER #ONNECTION 3UPPORT 'ROUP
3500/24)6% #!2% 3%26)#%3
2%3%!2#(
#LINICAL 2ESEARCH
#ANCER 2EGISTRY
-"0## 340( #!.#%2 02/'2!- !..5!, 2%0/24
' * )0#(!.)( #-.,# /.#)( -#. . & ' * ( , , !#-.,3 , *),. 4HE #ANCER 2EGISTRY IS A SPECIALIZED DATA SYSTEM DESIGNED FOR THE COLLECTION MANAGEMENT AND ANALYSIS OF DEMOGRAPHIC DIAGNOSTIC TREATMENT AND STAGING DATA ON CANCER PATIENTS TREATED AT -ARY "IRD 0ERKINS #ANCER #ENTER -"0## 4HE -"0## #ANCER 2EGISTRY REFERENCE DATE IS AND CONTAINS DATA ON
CASES !LL NEW CASES IDENTIlED ARE ABSTRACTED CODED AND STAGED IN ACCORDANCE WITH GUIDELINES SET BY THE !MERICAN #OLLEGE OF 3URGEONS !#O3 THE .ATIONAL #ANCER )NSTITUTE S 3URVEILLANCE %PIDEMIOLOGY AND %ND 2ESULTS 3%%2 PROGRAM AND THE ,OUISIANA 4UMOR 2EGISTRY (IGH IMPORTANCE IS PLACED ON DATA QUALITY USING THESE GUIDELINES AND A SAMPLE OF THE CASES IS REVIEWED BY A RADIATION ONCOLOGIST FOR QUALITY ASSURANCE /NCE PART OF THE REGISTRY DATABASE THESE CASES ARE FOLLOWED FOR THE LIFE OF THE PATIENT 4HE -"0## #ANCER 2EGISTRY MAINTAINS A FOLLOW UP RATE AVERAGING % EXCEEDING THE !#O3 MINIMUM STANDARD OF PERCENT FOR ALL ELIGIBLE ANALYTIC PATIENTS FROM THE CANCER REGISTRY REFERENCE DATE /F THE NEWLY ACCESSIONED CASES IN WERE ANALYTIC AND WERE NON ANALYTIC 4HE TOP lVE SITES TREATED WERE BREAST LUNG PROSTATE NON (ODGKIN S LYMPHOMA AND COLORECTAL
!NALYTIC CASES ARE THOSE RECEIVING ALL OR PART OF THE lRST COURSE OF THERAPY AT -ARY "IRD 0ERKINS #ANCER #ENTER WITHIN THE lRST FOUR MONTHS OF DIAGNOSIS .ON ANALYTIC CASES ARE THOSE NOT SEEN WITHIN THE lRST FOUR MONTHS FOLLOWING DIAGNOSIS
#OLORECTAL INCLUDES RECTUM COLON AND ANUS
!BBREVIATIONS - -ALE & &EMALE ! !NALYTICAL . ! .ON !NALYTICAL Not App.=Not !PPlicable 5NK 5NKNOWN
3ITE 'ROUP
4OTAL #LASS OF #ASES #ASE !
!,, 3)4%3
3EX
. ! -
.OT 5NK !PP
3TAGE &
)
)) ))) )6
",//$ "/.% -!22/7
,EUKEMIA
-YELOMA
/THER (EMATOPOIETIC
"2!).
"2%!34
$)'%34)6% 3934%-
!NUS !NAL #ANAL !NORECTUM
#OLON
%SOPHAGUS
0ANCREAS
2ECTUM 2ECTOSIGMOID
3MALL )NTESTINE
3TOMACH
&%-!,% '%.)4!,
#ERVIX 5TERI
6AGINA
,9-0(!4)# 3934%-
(ODGKIN S $ISEASE
.ON (ODGKIN S ,YMPHOMA
-!,% '%.)4!,
0ROSTATE
4ESTIS
/2!, #!6)49 0(!29.8
(YPOPHARYNX
-OUTH /THER ./3
.ASAL #AVITY 3INUS %AR
.ASOPHARYNX
3ALIVARY 'LAND -AJOR
4ONGUE
4ONSIL
2%30)2!4/29 ).42!4(/2!#)#
,ARYNX
,UNG "RONCHUS .ON 3MALL #ELL
,UNG "RONCHUS 3MALL #ELL
3+).
-ELANOMA OF 3KIN
/THER 3KIN #ANCER
3/&4 4)335%
5.+./7. /2 ),, $%&).%$
52).!29 42!#4
+IDNEY AND 2ENAL 0ELVIS
-"0## 340( #!.#%2 02/'2!- !..5!, 2%0/24
' * )0#(!.)( #-.,# /.#)( -#. . & 3ITE 'ROUP
4OTAL #LASS OF #ASE #ASES !
!,, 3)4%3
3EX
. ! -
.OT 5NK !PP
3TAGE &
)
)) ))) )6
/F THE NEWLY ACCESSIONED CASES IN WERE ANALYTIC AND WERE NON ANALYTIC 4HE TOP lVE SITES TREATED WERE BREAST LUNG PROSTATE NON (ODGKIN S LYMPHOMA AND COLORECTAL
",//$ "/.% -!22/7
,EUKEMIA
-YELOMA
"2!).
"2%!34
$)'%34)6% 3934%-
!NUS !NAL #ANAL !NORECTUM
#OLON
%SOPHAGUS
'ALLBLADDER
,IVER
4HE 2EGISTRY MAINTAINS CANCER DATA THAT IS AVAILABLE FOR USE BY CLINICAL AND ADMINISTRATIVE STAFF AT -"0## !LL INFORMATION COLLECTED IS KEPT COMPLETELY CONlDENTIAL $URING THE 2EGISTRY RECEIVED REQUESTS FOR STATISTICAL REPORTS INCLUDING ANALYTIC STUDIES ANNUAL STATISTICS RESEARCH ACTIVITIES QUALITY MANAGEMENT STUDIES REPORTING THE STATE CANCER REGISTRY AND REPORTING TO THE .ATIONAL #ANCER $ATA "ASE
0ANCREAS
.ICOLE -AGEE #42
2ECTUM 2ECTOSIGMOID
#ANCER 2EGISTRY -"0##
&%-!,% '%.)4!,
#ERVIX 5TERI
#ORPUS 5TERI
6ULVA
6AGINA
5TERUS ./3
,9-0(!4)# 3934%-
(ODGKIN S $ISEASE
.ON (ODGKIN S ,YMPHOMA
-!,% '%.)4!,
0ROSTATE
4ESTIS
/2!, #!6)49 0(!29.8
4ONGUE
&LOOR OF -OUTH
.ASAL #AVITY 3INUS %AR
4ONSIL
2%30)2!4/29 ).42!4(/2!#)#
,ARYNX
,UNG "RONCHUS .ON 3MALL #ELL
,UNG "RONCHUS 3MALL #ELL
3+).
-ELANOMA OF 3KIN
/THER 3KIN #ANCER
3/&4 4)335%
5.+./7. /2 ),, $%&).%$
52).!29 42!#4
+IDNEY AND 2ENAL 0ELVIS
5RETER
!BBREVIATIONS - -ALE & &EMALE ! !NALYTICAL . ! .ON !NALYTICAL Not !PP.=Not Applicable 5NK 5NKNOWN
-"0## 340( #!.#%2 02/'2!- !..5!, 2%0/24
-.*" #-.,# /.#)( -#. . & -.*" ( , , !#-.,3 , *),. h4HE INSTITUTIONS INVOLVED IN THE !PPROVALS 0ROGRAM REPRESENT A BROAD BASED NETWORK OF COMPREHENSIVE CANCER PROGRAMS THAT OFFER THE ENTIRE SPECTRUM OF CANCER CONTROL ACTIVITIES FROM PREVENTION TO REHABILITATION AND LONG TERM FOLLOW UP !PPROVAL IS GRANTED ONLY TO THOSE FACILITIES THAT HAVE VOLUNTARILY COMMITTED TO PROVIDE THE BEST IN CANCER DIAGNOSIS AND TREATMENT AND ARE ABLE TO COMPLY WITH ESTABLISHED #/# STANDARDS v &ROM THE !MERICAN #OLLEGE OF 3URGEONS #O# !PPROVED #ANCER 0ROGRAMS AT WWW FACS ORG
4HE 3T 4AMMANY 0ARISH (OSPITAL 340( #ANCER 2EGISTRY IS AN INTEGRAL PART OF THE #OMMISSION ON #ANCER !PPROVED #ANCER 0ROGRAM AND FUNCTIONS UNDER THE #ANCER #OMMITTEE TO COLLECT DATA ON CANCER TYPE STAGE AND TREATMENT RESULTS AND OFFERS LIFELONG PATIENT FOLLOW UP 4HESE CASES ARE REPORTED AS REQUIRED AND PER ()0!! STANDARDS TO THE !#O3 THE ,OUISIANA #ANCER 2EGISTRY ,42 THE .ATIONAL #ANCER $ATA "ASE .#$" AND THE 3URVEILLANCE %PIDEMIOLOGY AND %ND 2ESULTS 3%%2 PROGRAM OF THE .ATIONAL #ANCER )NSTITUTE 7HEN COMBINED WITH OTHER CANCER CASES NATIONALLY RESEARCHERS ARE ABLE TO IDENTIFY TRENDS IN CANCER INCIDENCE AND MORTALITY AS WELL AS PATTERNS IN DIAGNOSIS TREATMENT AND SURVIVAL $UE TO THE RESULTS OF (URRICANE +ATRINA THIS YEAR S REPORT REmECTS BOTH AND 2EGISTRY DATA 4HE NUMBER OF ANALYTICAL CASES FOR WAS NON ANALYTICAL CASES AND FOR NON ANALYTICAL CASES REmECTING A PERCENT INCREASE FOR ANALYTICAL AND PERCENT INCREASE IN NON ANALYTICAL CASES 4HESE INCREASES ARE ATTRIBUTED TO THE INCREASE IN POPULATION WITH THE RELOCATION OF (URRICANE +ATRINA EVACUEES INTO 3T 4AMMANY 0ARISH &OR BOTH YEARS THE MOST COMMON CANCER SITES WERE BREAST LUNG COLORECTAL LYMPHOMA AND PROSTATE
3ITE 'ROUP !,, 3)4%3 ",//$ "/.% -!22/7 ,EUKEMIA -YELOMA /THER (EMATOPOIETIC "/.% "2!). "2%!34 $)'%34)6% 3934%!NUS !NAL #ANAL !NORECTUM #OLON %SOPHAGUS 'ALLBLADDER ,IVER 0ANCREAS 2ECTUM 2ECTOSIGMOID 3MALL )NTESTINE 3TOMACH /THER $IGESTIVE %.$/#2).% 4HYROID /THER %NDOCRINE %9% &%-!,% '%.)4!, #ERVIX 5TERI #ERVIX )N 3ITU #A #ORPUS 5TERI /VARY 6AGINA 6ULVA ,9-0(!4)# 3934%(ODGKIN S $ISEASE .ON (ODGKIN S ,YMPHOMA
-!,% '%.)4!, 0ROSTATE 4ESTIS /2!, #!6)49 0(!29.8 (YPOPHARYNX -OUTH /THER ./3 3ALIVARY 'LANDS -AJOR 4ONGUE 4ONSIL 2%30)2!4/29 ).42!4(/2!#)# ,ARYNX ,UNG "RONCHUS .ON 3MALL #ELL ,UNG "RONCHUS 3MALL #ELL 0LEURA 2%42/0%2)4/.%53+). -ELANOMA OF 3KIN /THER 3KIN #ANCER 3/&4 4)335% 5.+./7. /2 ),, $%&).%$ 52).!29 42!#4 "LADDER +IDNEY AND 2ENAL 0ELVIS
4OTAL #ASES
#LASS
3EX
! . !
&
!*## #OLLABORATIVE .OT 5NK 3TAGE AT $IAGNOSIS !PP ) )) ))) )6
.OTE 3EX AND !*## #OLLABORATIVE 3TAGE !NALYTICAL #ASES ONLY !BBREVIATIONS - -ALE & &EMALE ! !NALYTICAL . ! .ON !NALYTICAL Not App.=Not Applicable; 5NK 5NKNOWN !*## !MERICAN *OINT #OMMISSION ON #ANCER
3TAGING IS BASED ON MIXED !*## #OLLABORATIVE STAGING
)NCLUDES OR MORE LYMPHOMA CASES CODED TO NON LYMPHATIC SITES
-"0## 340( #!.#%2 02/'2!- !..5!, 2%0/24
-.*" #-.,# /.#)( -#. . & 3ITE 'ROUP !,, 3)4%3 ",//$ "/.% -!22/7 ,EUKEMIA -YELOMA /THER (EMATOPOIETIC "2!). "2%!34 $)'%34)6% 3934%"ILE $UCTS #OLON %SOPHAGUS 'ALLBLADDER ,IVER 0ANCREAS 2ECTUM 2ECTOSIGMOID 3MALL )NTESTINE 3TOMACH %.$/#2).% 4HYROID &%-!,% '%.)4!, #ERVIX 5TERI #ERVIX )N 3ITU #A #ORPUS 5TERI /VARY 6AGINA 6ULVA /THER &EMALE 'ENITAL ,9-0(!4)# 3934%(ODGKIN S $ISEASE .ON (ODGKIN S ,YMPHOMA
-!,% '%.)4!, 0ROSTATE /2!, #!6)49 0(!29.8 ,IP 3ALIVARY 'LANDS -AJOR 4ONGUE 4ONSIL 0%2)4/.%52%30)2!4/29 ).42!4(/2!#)# ,ARYNX ,UNG "RONCHUS .ON 3MALL #ELl ,UNG "RONCHUS 3MALL #ELL 3+). -ELANOMA OF 3KIN /THER 3KIN #ANCER 3/&4 4)335% 5.+./7. /2 ),, $%&).%$ 52).!29 42!#4 "LADDER +IDNEY AND 2ENAL 0ELVIS 5RETER
4OTAL #ASES
#LASS
3EX
! . ! &
.OT !*## #OLLABORATIVE 5NK !PP 3TAGE AT $IAGNOSIS
) )) ))) )6
)N SPITE OF (URRICANE +ATRINA S EFFECTS ON OUR HOSPITAL AND STAFF THE #ANCER 2EGISTRY KEPT ALL REQUIRED STANDARDS INCLUDING FOLLOW UP AND CONTINUED TO SERVE AS A VALUABLE DATA RESOURCE PROVIDING REPORTS ON SELECTED INFORMATION TO PHYSICIANS AT MONTHLY TUMOR CONFERENCES TO HOSPITAL WIDE DEPARTMENTS AND EVEN OUTSIDE SOURCES !LL DATA SUBMISSIONS WERE REVIEWED AND EDITED IN COMPLIANCE WITH STANDARDS AND WAS REmECTED IN OUR COMMENDATION RATING FOR QUALITY OF .#$" DATA SUBMISSION IN OUR CANCER PROGRAM APPROVAL SURVEY "ECAUSE OF THE 2EGISTRY S CONTINUAL EDUCATIONAL EFFORTS WITH MEMBERS OF THE #ANCER #OMMITTEE AND MEDICAL STAFF THE HOSPITAL WAS AWARDED ANOTHER COMMENDATION FOR COMPLETENESS OF PHYSICIAN STAGING DURING OUR SURVEY )N THE LAST TWO YEARS THE 2EGISTRY ASSISTED THE 0ATHOLOGY $EPARTMENT IN WORKING OUT A SYSTEM TO ENSURE COMPLIANCE WITH #OLLEGE OF !MERICAN 0ATHOLOGY #!0 0ROTOCOLS AND PARTICIPATED IN THE 3%%2 0ATTERNS OF #ARE 3TUDY ON SIX SPECIlC SITES AND IN THE 3%%2 2ELIABILITY 3TUDY NEW 3ITE 3PECIlC -ULTI 0RIMARY (ISTOLOGY ON #OLON 2ENAL 0ELVIS
"EVERLY & 6ILLEMUER #42 #ANCER 2EGISTRY 340(
.OTE 3EX AND !*## #OLLABORATIVE 3TAGE !NALYTICAL #ASES ONLY !BBREVIATIONS - -ALE & &EMALE ! !NALYTICAL . ! .ON !NALYTICAL Not App.=Not Applicable; 5NK 5NKNOWN !*## !MERICAN *OINT #OMMISSION ON #ANCER
3TAGING IS BASED ON MIXED !*## #OLLABORATIVE STAGING
)NCLUDES OR MORE LYMPHOMA CASES CODED TO NON LYMPHATIC SITES
-"0## 340( #!.#%2 02/'2!- !..5!, 2%0/24
) /- )( *,)-. . ( ,
/VERVIEW OF 0ROSTATE #ANCER 4HE !MERICAN #ANCER 3OCIETY !#3 ESTIMATES THAT CLOSE TO NEW CASES OF PROSTATE CANCER WILL BE DIAGNOSED IN AND THAT APPROXIMATELY MEN WILL DIE FROM THIS DISEASE 0ROSTATE CANCER IS THE MOST FREQUENTLY DIAGNOSED CANCER IN MEN ACCOUNTING FOR PERCENT OF ALL NEW MALE CANCER CASES AND IS THE THIRD LEADING CAUSE OF CANCER DEATH IN MEN #URRENTLY A MAN S OVERALL LIFETIME RISK OF DEVELOPING PROSTATE CANCER IS PERCENT IN THE 5NITED 3TATES /NE IN SIX MEN WILL DEVELOP PROSTATE CANCER IN THEIR LIFETIME 4HE INCIDENCE OF PROSTATE CANCER IS SIGNIlCANTLY INCREASED IN !FRICAN !MERICAN MALES VERSUS WHITE MALES /VERALL INCIDENCE RATES HAVE INCREASED SUBSTANTIALLY OVER THE LAST YEARS A TREND RELATED LARGELY TO INCREASING USE OF PROSTATE SPECIlC ANTIGEN 03! BLOOD TESTING AND ITS INCREASING ACCEPTANCE AS A SCREENING TEST IN MEN YOUNGER THAN AGE 0ROSTATE CANCER INCIDENCE RATES IN MALES OVER AGE REMAIN RELATIVELY UNCHANGED $EATH RATES HAVE BEEN ON THE DECLINE IN BOTH !FRICAN !MERICAN AND WHITE MALES SINCE THE EARLY S BUT DEATH RATES ARE STILL TWICE AS HIGH IN !FRICAN !MERICAN MALES
2ISK &ACTORS !#3 CITES THE ONLY WELL ESTABLISHED RISK FACTORS FOR PROSTATE CANCER AS AGE ETHNICITY AND FAMILY HISTORY OF THE DISEASE -ORE THAN PERCENT OF PROSTATE CANCER OCCURS IN MEN AGE AND OLDER &OR REASONS THAT ARE NOT TOTALLY CLEAR !FRICAN !MERICAN AND *AMAICAN MEN HAVE THE HIGHEST INCIDENCE OF PROSTATE CANCER IN THE WORLD 'LOBALLY THIS CANCER IS COMMON IN .ORTH !MERICA AND .ORTHWEST %UROPE BUT IS RARE IN !SIA OR 3OUTH !MERICA 2ECENT GENETIC STUDIES SHOW THAT A STRONG FAMILIAL PREDISPOSITION MAY BE RESPONSIBLE FOR OF ALL PROSTATE CANCERS
3CREENING 2ECOMMENDATIONS "OTH THE 03! BLOOD TEST AND DIGITAL RECTAL EXAM $2% TO EXAMINE THE PROSTATE GLAND SHOULD BE OFFERED ANNUALLY TO ALL MEN WITH NO FAMILY HISTORY OF THE DISEASE BEGINNING AT AGE !FRICAN !MERICAN MALES OR ANY MAN WITH A lRST DEGREE RELATIVE DIAGNOSED WITH PROSTATE CANCER BEFORE THE AGE OF SHOULD BEGIN ANNUAL SCREENING AT AGE !T THIS TIME THERE IS NOT ENOUGH DATA TO ENCOURAGE OR DISCOURAGE EARLY TESTING FOR PROSTATE CANCER FOR MEN WHO ARE AT AVERAGE RISK OF THE DISEASE !LL MEN REGARDLESS OF AGE SHOULD DISCUSS THE BENElTS AND LIMITATIONS OF TESTING WITH THEIR PHYSICIAN IN ORDER TO MAKE AN INFORMED DECISION ABOUT THEIR INDIVIDUAL CARE
)NITIAL 0ROSTATE #ANCER $IAGNOSIS 4HE INITIAL DETECTION OF PROSTATE CANCER IS USUALLY BASED ON EITHER AN ABNORMAL 03! BLOOD TEST OR $2% ! TRANSRECTAL ULTRASOUND GUIDED NEEDLE BIOPSY IS MOST COMMONLY USED TO OBTAIN A TISSUE SPECIMEN ! PRIMARY AND SECONDARY 'LEASON S 3CORE IS USED TO GRADE THE CANCER #LINICAL STAGING DETERMINES THE EXTENT OF THE DISEASE USING THE !*## !MERICAN *OINT #OMMITTEE ON #ANCER 4.- CLASSIlCATION SYSTEM WHICH EVALUATES THE SIZE OF THE TUMOR WHETHER LYMPH NODES ARE INVOLVED AND WHETHER OR NOT THE CANCER HAS SPREAD TO OTHER MORE DISTANT AREAS OF THE BODY #ONSIDERATION IS ALSO GIVEN TO THE PATIENT S LIFE EXPECTANCY AND WHETHER THE CANCER IS CAUSING SYMPTOMS 0ROSTATE CANCER IS OFTEN A CHRONIC DISEASE
. & # *,)-. . ( , -. .#-.# & )0 ,0# 1 )'* ,#-)( ( 0- -.*" ( "' ,% , *),. $%-/'2!0()#3 3EX -ALE !GE !T $IAGNOSIS 2ACE 7HITE "LACK (ISPANIC !SIAN )NSURANCE .OT )NSURED 0RIVATE )NSURANCE -ANAGED #ARE -EDICARE -EDICARE W 3UPPLEMENT !*## 3TAGE ) )) ))) )6 5.+ (ISTOLOGY !DENOCARCINOMA ./3 /THER 3PECIlED 4YPES &IRST #OURSE OF 4REATMENT 3URGERY /NLY 2ADIATION /NLY 3URGERY 2ADIATION 2ADIATION (ORMONE 4HERAPY 3URGERY (ORMONE 4HERAPY (ORMONE 4HERAPY /NLY /THER 3PECIlED 4REATMENT #OMBINATION .O ST #OURSE 2X &IRST #OURSE OF 3URGERY .O 3URGERY ,OCAL 4UMOR $ESTRUCTION 3UBTOTAL OR 3IMPLE 0ROSTATECTOMY 2ADICAL 0ROSTATECTOMY 4YPE OF 2ADIATION !DMINISTERED .O 2ADIATION "EAM 2ADIATION "RACHYTHERAPY 2ADIATION 4HERAPY ./3 3YSTEMIC 4HERAPY .O 3YSTEMIC 4HERAPY (ORMONE 4HERAPY !LONE
), .
.#$" N
340(
N
-AY NOT EQUAL DUE TO ROUNDING ONLY COMPARABLE .#$" DATA INCLUDED
)NCLUDES PATIENTS DIAGNOSED AND OR TREATED AT 340( AND REFERRED TO -"0## OR ANOTHER RADIATION CENTER
-"0## 340( #!.#%2 02/'2!- !..5!, 2%0/24
. & #0 3 , ) - ,0 -/,0#0 & , .
AND MEN WITHOUT SYMPTOMS MAY NOT BENElT FROM IMMEDIATE TREATMENT ESPECIALLY IF THEY ARE IN OTHERWISE POOR HEALTH
#OMPARISONS BY !*## 3TAGE FOR 0ROSTATE #ANCER #ASES "ETWEEN .#$"
.#$" 3TATE OF ,OUISIANA (OSPITALS /NLY
340( AND 2EFERRED TO !NOTHER 2ADIATION #ENTER AND 4HOSE 4REATED /NLY AT 340( -"0##
4REATMENT
!*## 3TAGE !LL 3TAGES ) )) ))) )6
.#$"
.#$"
34!4% /& ,/5)3)!.!
N
N
340( 2%&%22%$ 4/ ! 2!$)!4)/. #%.4%2 N
<
340( 2%&%22%$ 4/ -"0## N
< <
!*## !MERICAN *OINT #OMMISSION ON #ANCER
.#$" DATA REPORTED FROM (OSPITALS OF ALL TYPES
.#$" DATA REPORTED FROM (OSPITALS OF ALL TYPES < NO COMPARISON DATA
. & ., .' (. )'* ,#-)( -.*" ' * *,)-. . -
-IXED 4.- 3TAGE 3TAGE ) 3TAGE )) 3TAGE ))) 3TAGE )6 !GE AT $IAGNOSIS -EAN AGE -EDIAN AGE 2ACE 7HITE !FRICAN !MERICAN (AWAIIAN 3URVIVAL /BSERVED
0ROSTATE #ANCER /UTCOMES 3TUDY
)
3URGERY "RACHYTHERAPY 2ADIATION %XTERNAL "EAM 2ADIATION N N
4OTAL #ASES
.O 2ADIATION
N
N
<
< <
<
<
-AY NOT EQUAL DUE TO ROUNDING
%XCLUDES UNKNOWN AND NOT APPLICABLE STAGES < .O COMPARISON DATA
-ANY FACTORS INmUENCE TREATMENT OPTIONS INCLUDING AGE STAGE OF THE CANCER THE PRESENCE OF OTHER CO EXISTING OR CHRONIC CONDITIONS AND PROGNOSTIC INDICATORS SUCH AS 03! LEVELS AND THE TOTAL 'LEASON SCORE .UMEROUS TREATMENT MODALITIES ARE AVAILABLE THAT ALLOW FOR INDIVIDUALIZED TREATMENT PLANNING 3URGERY AND EXTERNAL BEAM RADIATION OR BRACHYTHERAPY IMPLANTATION OF RADIOACTIVE SEED IMPLANTS AT THE TUMOR SITE MAY BE USED TO TREAT EARLY STAGE DISEASE #OMBINATIONS OF CHEMOTHERAPY HORMONE THERAPY AND OR RADIATION THERAPY MAY BE USED TO TREAT ADVANCED DISEASE OR AS ADJUVANT TREATMENT FOR EARLY STAGE DISEASE h7ATCHFUL WAITING v OR OBSERVATION MAY BE APPROPRIATE FOR OLDER MEN WHO HAVE LESS AGGRESSIVE TUMORS OR LIMITED LIFE EXPECTANCY 0ROSTATE CANCER TREATMENT GUIDELINES ESTABLISHED BY THE .ATIONAL #OMPREHENSIVE #ANCER .ETWORK .##. ARE AVAILABLE FOR PATIENTS AND CLINICIANS ON THE !#3 WEBSITE WWW CANCER ORG AND THE .##. WEBSITE WWW NCCN ORG 4HE #ANCER #OMMITTEE COMPARED PATTERNS OF TREATMENT AND OUTCOMES SURVIVAL OF PATIENTS DIAGNOSED AND TREATED WITH PROSTATE CANCER AT 340( AND -"0## WITH THE .ATIONAL #ANCER $ATA "ASE .#$" "ENCHMARK 2EPORT DURING THE REPORTING PERIOD 4ABLE PROVIDES A STATISTICAL OVERVIEW OF COMPARISONS WITH NO VARIATIONS OF SIGNIlCANCE NOTED IN AGE PRESENTING STAGE OR HISTOLOGIES ! HIGHER PERCENTAGE OF WHITE MALES AND MANAGED CARE PATIENTS WAS NOTED WHEN COMPARED TO .#$" DATA 4REATMENT DISTRIBUTION PATTERNS WERE QUITE SIMILAR TO NATIONAL DATA WITH THE EXCEPTION OF BRACHYTHERAPY WHERE THERE WAS A NOTICABLE INCREASE IN PATIENTS TREATED AT 340( -"0## WITH THIS TREATMENT OPTION 4HE OBSERVED lVE YEAR SURVIVAL RATE OF PATIENTS TREATED AT 340( AND REFERRED FOR RADIATION WERE COMPARED TO PATIENTS TREATED AT 340( AND REFERRED TO -"0## FOR RADIATION TREATMENT /VERALL SURVIVAL RATES 4ABLE FOR ALL STAGES FOR PATIENTS TREATED AT 340( WAS PERCENT WHICH WAS COMPARABLE TO NATIONAL AND STATE DATA (OWEVER PATIENTS RECEIVING TREATMENT AT 340( AND RADIATION AT -"0## WAS PERCENT WHICH WAS HIGHER THAN NATIONAL OR STATE DATA 4HIS INCREASE IN SURVIVAL COULD BE ATTRIBUTED TO THE INTRODUCTION AND UTILIZATION OF BRACHYTHERAPY AS A TREATMENT FOR PROSTATE CANCER IN AND THE FACT THAT THIS OPTION IS MOST COMMONLY UTILIZED FOR EARLY STAGE DISEASE 4HE #OMMITTEE ALSO WANTED TO COMPARE SURVIVAL IN PROSTATE CANCER CASES TREATED WITH NO RADIATION SURGERY WITH EXTERNAL BEAM RADIATION OR BRACHYTHERAPY WITH OR WITHOUT EXTERNAL BEAM RADIATION TO DETERMINE DIFFERENCES IN TREATMENT AND SURVIVAL 4ABLE ! TOTAL OF CASES DIAGNOSED BETWEEN WERE INCLUDED /F THOSE CASES RECEIVED SURGERY WITH EXTERNAL BEAM RADIATION PATIENTS RECEIVED BRACHYTHERAPY WITH OR WITHOUT EXTERNAL BEAM RADIATION AND PATIENTS DID NOT REQUIRE ANY TYPE OF RADIATION TREATMENT 4HE MAJORITY CONTINUED ON NEXT PAGE
-"0## 340( #!.#%2 02/'2!- !..5!, 2%0/24
PERCENT OF THE PATIENTS WERE DIAGNOSED WITH EARLY STAGE CANCERS RESULTING IN A OBSERVED SURVIVAL RATE OF PERCENT )N THE GROUP THAT RECEIVED BRACHYTHERAPY WITH OR WITHOUT EXTERNAL BEAM RADIATION OBSERVED SURVIVAL RATES WERE PERCENT MOST LIKELY RELATED AGAIN TO THE EARLY STAGE OF DISEASE
$ISCUSSION 4HE ADOPTION AND PROMOTION OF 03! AND $2% AS PROSTATE CANCER SCREENING TOOLS IN THE EARLY S HAS RESULTED IN THIS CANCER BEING DIAGNOSED IN EARLIER STAGES WHERE MORE TREATMENT OPTIONS ARE AVAILABLE 2ESEARCH IS PROVIDING MORE AND MORE INFORMATION ABOUT THE CLINICAL PROGRESSION OF PROSTATE CANCER WHICH WILL IMPACT THE AVAILABILITY OF ADDITIONAL MANAGEMENT OPTIONS IN THE FUTURE SIMILAR TO WHAT HAS BEEN SEEN IN BREAST CANCER MANAGEMENT 4HE UTILIZATION OF PROSTATE BRACHYTHERAPY HAS ALREADY DIMINISHED WITH THE INTRODUCTION OF )NTENSITY -ODULATED 2ADIATION 4HERAPY )-24 WHICH PROVIDES ACCURATE RADIATION WHILE MINIMIZING THE IMPACT ON NORMAL SURROUNDING TISSUES 340( AND -"0## WILL CONTINUE TO WORK WITH !#3 LOCAL UROLOGISTS AND OTHER LOCAL ORGANIZATIONS TO PROMOTE SCREENING IN TARGET POPULATIONS WITH SPECIAL EMPHASIS ON HIGH RISK INDIVIDUALS AND THOSE WHO ARE UNINSURED OR UNDERINSURED AND MIGHT NOT OTHERWISE RECEIVE APPROPRIATE SCREENING %FFORTS TO DATE HAVE EXPANDED OUTREACH SCREENINGS INTO OTHER AREAS SUCH AS 7ASHINGTON 0ARISH AND &%-! HOUSING PARKS AS NEEDED IN THE SOUTHEAST ,OUISIANA AREA -ORE EFFORTS HAVE ALSO BEEN PLACED ON EDUCATION OF !FRICAN !MERICAN MALES WITH AN OBVIOUS INCREASE IN THE THE NUMBER OF !FRICAN !MERICAN ATTENDEES AT SCREENINGS OVER THE LAST THREE YEARS 7ITH THE INmUX OF (ISPANICS EFFORTS ARE UNDERWAY TO REACH THIS POPULATION WITH EDUCATION AND SCREENING OPPORTUNITIES AS WELL &OR MORE INFORMATION ON FREE SCREENING OPPORTUNITIES FOR PROSTATE AND OTHER CANCERS CONTACT THE -"0## # ! 2 % .ETWORK AT OR THE 340( #ANCER 2ESOURCE #ENTER AT
3UNIL 0UROHIT -$ "OARD #ERTIlED 5ROLOGY
2EFERENCES #ANCER &ACTS AND &IGURES !MERICAN #ANCER 3OCIETY .EW 9ORK #ANCER 0REVENTION %ARLY $ETECTION &ACTS AND &IGURES !MERICAN #ANCER 3OCIETY .EW 9ORK .ATIONAL #ANCER $ATA "ASE .#$" #OMMISSION ON #ANCER !MERICAN #OLLEGE OF 3URGEONS "ENCHMARK 2EPORTS WWW FACS ORG
!&)-- ,3
)
. ,'-
!NALYTIC #LASS OR ! REPORTABLE CANCER CASE FOR -"0## OR 340( THAT REQUIRES ABSTRACTING AND LIFETIME FOLLOW UP #LASS A CASE hDIAGNOSED ONLYv AT A FACILITY #LASS A CASE hDIAGNOSED AND TREATEDv AT A FACILITY #LASS A CASE hTREATED ONLYv AT A FACILITY #LASS A CASE DIAGNOSED AND TREATED ONLY IN A STAFF PHYSICIAN S OFlCE &OLLOW UP 4HE YEARLY UPDATING OF ALL ANALYTIC CASES IN THE REGISTRY WITH PATIENT S LAST DATE OF CONTACT VITAL STATISTICS AND CANCER STATUS )NCIDENCE 4HE NUMBER OF NEW CASES OF A DISEASE THAT OCCUR IN A POPULATION EACH YEAR ,OCALIZED #ANCER: ! CANCER STILL CONlNED TO ITS SITE OF ORIGIN -ALIGNANT 4UMOR ! MASS OF CANCER CELLS THAT MAY INVADE SURROUNDING TISSUES OR SPREAD METASTASIZE TO DISTANT AREAS OF THE BODY -ETASTASIS 4HE SPREAD OF CANCER CELLS TO DISTANT AREAS OF THE BODY BY WAY OF THE LYMPH SYSTEM OR BLOODSTREAM -ORTALITY ! MEASURE OF THE RATE OF DEATH FROM A DISEASE WITHIN A GIVEN POPULATION .ON ANALYTIC #LASS OR ! NON REPORTABLE CASE FOR -"0## OR 340( THAT IS ABSTRACTED ONLY WITH NO FOLLOW UP #LASS A CASE INITIALLY DIAGNOSED AND TREATED ELSEWHERE #LASS A CASE INITIALLY DIAGNOSED AND TREATED HERE BOTH OF WHICH RECEIVE SUBSEQUENT TREATMENT AT -"0## OR 340( #LASS 0ATHOLOGY REPORT READ ONLY
0ROSTATE #ANCER 4REATMENT 'UIDELINES FOR 0ATIENTS 6ERSION 6 3EPTEMBER WWW NCCN ORG 0ROSTATE #ANCER 4REATMENT #LINICAL 0RACTICE 'UIDELINES FOR #LINICIANS 6ERSION WWW NCCN ORG -"0## 340( #!.#%2 02/'2!- !..5!, 2%0/24
2EGIONAL )NVOLVEMENT 4HE SPREAD OF CANCER FROM ITS ORIGINAL SITE TO NEARBY AREAS BUT NOT TO DISTANT SITES SUCH AS OTHER ORGANS 3TAGE OF $ISEASE ! DESCRIPTION OF THE EVENT OF TUMOR SPREAD AS DETERMINED AT THE TIME OF THE lRST COURSE OF TREATMENT 3TAGE IS CLASSIlED ACCORDING TO SPECIlC CRITERIA 3%%2 3UMMARY 3TAGING 'UIDE IS USED TO CATEGORIZE MOST SITES OF CANCER INTO THE STAGE CATEGORIES IN SITU LOCALIZED REGIONAL NODES EXTENSION OR BOTH DISTANT AND UNKNOWN 4HE STAGING GUIDE PROVIDES SITE SPECIlC DElNITIONS FOR EACH STAGE CATEGORY TO ASSURE CONSISTENCY 4.- 3TAGING TUMOR NODES METASTASIS 5SED TO STAGE CANCER CASES FOLLOWING THE 4.- CLASSIlCATION PUBLISHED BY 4HE !MERICAN *OINT #OMMITTEE ON #ANCER !*## IN ITS -ANUAL FOR 3TAGING OF #ANCER 3URVIVAL 2ATE 4HE PERCENTAGE OF SURVIVORS WITH NO TRACE OF DISEASE WITHIN A CERTAIN PERIOD OF TIME AFTER DIAGNOSIS OR TREATMENT &OR CANCER A lVE YEAR SURVIVAL RATE IS OFTEN GIVEN 4HIS DOES NOT MEAN THAT PEOPLE CANNOT LIVE MORE THAN lVE YEARS OR THAT THOSE WHO LIVE FOR lVE YEARS ARE NECESSARILY PERMANENTLY CURED
COMMUNITY SUPPORT GROUPS AND ACTIVITIES Bereavement Support Group Open to anyone in the community who has experienced a loss from the death of a loved one. The group is held in short sessions. 871.5976 Better Breathers Support Group Designed for adults with lung disease interested in better living and their caregivers. 898.3785 Breast Cancer Support Group Designed to provide support and information to individuals diagnosed with cancer. Meets on the second Tuesday of each month. 612.2111
Children’s Grief Support Group
Lymphedema Prevention Clinic
Open to children ages 7-12 in the community who have experienced the death of a loved one. 871.5976
One-on-one assessments with a certified lymphedema therapist are offered free of charge periodically throughout the year to breast cancer survivors who have had lymph nodes removed. 888.616.4687
Genetic Cancer Risk Assessment & Counseling Program Provides genetic counseling and screening services at no cost to individuals at high risk for cancer development to help patients and their families make informed decisions about their medical options, including screening for early detection, ways to reduce personal risk and genetic testing. Co-sponsored by MBPCC’s C.A.R.E. Network, STPH and Hematology Oncology Specialists Foundation. 898.4581 Hospice Volunteer Training
Cancer Survivors Day Held in June, National Cancer Survivors Day provides support and recognition to individuals within our community who have had a cancer diagnosis, and their caregivers, and to celebrate survivorship. Co-sponsored by MBPCC’s C.A.R.E. Network, STPH and Hematology Oncology Specialists Foundation. 898.4581 Cancer Connection Support Group This monthly support group is for individuals, family members and friends who are challenged by a diagnosis of cancer. It provides an atmosphere for expressing thoughts, feelings and expectations. Participants can share experiences and learn to adapt to lifestyle changes. Meetings are the third Wednesday of each month. 898-4581 Caregiver Connection Support Group This monthly support group is specifically for caregivers to share hope and support in caring for loved ones. 871.5974 Caring for the Caregiver Provided throughout the year for caregivers, with hands on demonstrations to help families know how to turn, position and lift their loved one. Information is also provided caring for themselves as a caregiver. 871.5976
Offered to those interested in becoming a Hospice volunteer. Volunteers are used in direct patient care, office support, bereavement care, community education and fundraising events. 871.5976 Hospice 101 Provided for those interested in learning more about Hospice, care of the terminally ill and compassionate care for those at the end of life. 8715976 Look Good, Feel Better Offers skin, nail and hair care tips that can enhance appearance and improve self-image while undergoing cancer treatment. Our professionals will help you with a 12-step make-up guide, choosing and caring for a wig and dealing with skin changes. Cosmetics provided. Held monthly. Co-sponsored by ACS and STPH. 898.4481 Lunch and Learn Educational Programs Offered frequently throughout the year on a variety of topics for individuals diagnosed with cancer, their families, friends and caregivers who support them. 898.4481
Reach to Recovery Specially trained breast cancer survivors volunteer to provide one-on-one support to cope with breast cancer. They respond personally to concerns of those facing breast cancer diagnosis, treatment, recurrence or recovery. Cosponsored by ACS and STPH. 612.2111 Smoking Cessation Classes scheduled throughout the year. When combined with other smoking cessation efforts, structured classes can greatly increase the chances of quitting for good. Funding provided by The Louisiana Campaign for TobaccoFree Living. Co-sponsored by MBPCC’s C.A.R.E. Network and STPH. 898.4581 Wig Resource Center This community service program offers wigs, turbans, hats and scarves at no cost to women undergoing cancer treatment. Our private fitting area is located in the Cancer Resource Center. Co-sponsored by ACS and STPH. Call 898.4481 for more information.
-ARY "IRD 0ERKINS #ANCER #ENTER 3TARBRUSH #IRCLE #OVINGTON ,!
WWW MARYBIRD ORG
WWW STPH ORG
-"0## 340( #!.#%2 02/'2!- !..5!, 2%0/2
./. 02/&)4 /2' 5 3 0OSTAGE
0!)$
0ERMIT .O "ATON 2OUGE ,!